Patrys Limited (ASX:PAB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
Jul 24, 2025, 4:10 PM AEST

Patrys Company Description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.

The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs.

In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications.

Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

Patrys Limited
Patrys logo
CountryAustralia
Founded2006
IndustryBiotechnology
SectorHealthcare
Employees10
CEOJames Campbell

Contact Details

Address:
96-100 Albert Road
Melbourne, 3205
Australia
Phone61 3 9670 3273
Websitepatrys.com

Stock Details

Ticker SymbolPAB
ExchangeAustralian Securities Exchange
Fiscal YearJuly - June
Reporting CurrencyAUD
ISIN NumberAU000000PAB9
SIC Code2836

Key Executives

NamePosition
Dr. James A. Campbell B.Sc., MBA, Ph.D.MD, Chief Executive Officer and Executive Director
Stefan RossCompany Secretary